Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 273)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 19.01.24 22:21:17 von
neuester Beitrag 19.01.24 22:21:17 von
Beiträge: 2.935
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 0
Gesamt: 345.742
Gesamt: 345.742
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: RXK3
1,2380
EUR
+6,91 %
+0,0800 EUR
Letzter Kurs 08:54:03 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 1,1514 | +30,84 | |
| 0,5150 | +30,05 | |
| 0,9150 | +21,84 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,8000 | -18,64 | |
| 46,00 | -19,44 | |
| 2,4600 | -21,66 | |
| 36,70 | -22,87 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Korrigiere
Ich hatte es mit DNDN...aber vor dem grossen Crash
Ich hatte es mit DNDN...aber vor dem grossen Crash
Hey Leute,
mir gefällts....
mir gefällts....
merci...guter Bericht.
Galena, die neue Dendreon.
Galena, die neue Dendreon.
Trading Spotlight
schon gelesen? Quelle: Smallcap Network
It may look like little more than a choppy mess with just a quick glance at Galena Biopharma Inc. (NASDAQ:GALE). But, the more you study the chart - and the company - the more you realize there's enough long-term potential from the company's pipeline to keep spurring GALE in a generally-upward direction. In fact, the bulls look like they're on the verge of taking Galena Biopharma out of second gear and putting it into third. As such, it may not be a bad bet at this point.
Don't sweat it if you haven't heard of GALE - most people haven't. It's a $249 million biotech outfit that isn't actually driving any revenue yet (more on that in a moment). As veteran biotechnology traders can attest, however, that's hardly necessary. At the root of most speculative biotech gains are the mere promise of a new drug, and if there's one thing Galena Biopharma has plenty of in the pipeline, its promise.
One of the most compelling therapies in the works for Galena is NeuVax as a treatment for NP breast cancer. That trial is now in Phase 3, and represents the company's "next big hot button." NeuVax isn't just for breast cancer, though. GALE is also in Phase 2 trials with NeuVax plus Herceptin as a treatment for breast cancer, is in Phase 2 trials using the drug as a treatment for a different type of breast cancer, and the drug is even being tried as a therapy for prostate cancer; that trial is a Phase 1 test right now.
It can be a little unsettling for investors to know a company's nearly-entire pipeline is the same basic compound; if it doesn't work for one cancer, odds are good it won't work for others. Galena Biopharma Inc. isn't off-base with NeuVax, however. It's the real deal, and though it may not be approved for every indication it's being tested for, we've seen enough efficacy to offer hope for GALE investors. In the primary breast cancer trial, for instance, at 24 months, NeuVax patients were disease-free versus 86.8% of patients not taking the drug. At 60 months, 89.7% of NeuVax patients were disease-free versus 79.6% of patients in the control group.
Thing is, GALE isn't a "right here, right now" idea on the potential of NeuVax alone... there's a bit of an opportunistic angle here, fueled by a combination of timing and a technical catalysts (that may be tied together anyway).
As for the catalyst, while at Galena Biopharma may not have anything on the market and driving revenue yet, what's easy to miss about the company is that it has an approved drug it plans to begin marketing this year.
It's Abstral, for pain management in cancer patients. You've not heard much about it because it was approved a couple of years ago when a different company developed it and got the drug approved; Galena only decided recently to begin making it and selling it after buying the rights to it in the middle of this year.
Meanwhile, it was recently approved for use in Japan, so it may be over the proverbial hump in terms of getting enough revenue size and scale to make it with Galena's while. With much of this news staying off the radar, however, GALE is still something of an undiscovered opportunity. That condition is changing rapidly, however, if the shape of the GALE chart is any indication.
There's no denying GALE has been rallying nicely - even if modestly - since early 2012. But, the buying effort may be about to explode if shares can just get over the horizontal hurdle around $2.50 (which may be a possibility today). The convergence of the rising support line and a horizontal ceiling is putting a serious squeeze on the stock, and it looks like the bulls are drawing a tougher line in the sand than the bears are. We're also seeing more bullish volume than bearish volume here, so once the wedge pattern really starts to crumble, the flow should be an upward one. Indeed, some would argue that it already is. However, you see it, there's no denying that the news as well as the stock's momentum are starting to work together for the good of shareholders. This thing could get explosive real soon.
Grüsse aus der Schweiz
Zubi
It may look like little more than a choppy mess with just a quick glance at Galena Biopharma Inc. (NASDAQ:GALE). But, the more you study the chart - and the company - the more you realize there's enough long-term potential from the company's pipeline to keep spurring GALE in a generally-upward direction. In fact, the bulls look like they're on the verge of taking Galena Biopharma out of second gear and putting it into third. As such, it may not be a bad bet at this point.
Don't sweat it if you haven't heard of GALE - most people haven't. It's a $249 million biotech outfit that isn't actually driving any revenue yet (more on that in a moment). As veteran biotechnology traders can attest, however, that's hardly necessary. At the root of most speculative biotech gains are the mere promise of a new drug, and if there's one thing Galena Biopharma has plenty of in the pipeline, its promise.
One of the most compelling therapies in the works for Galena is NeuVax as a treatment for NP breast cancer. That trial is now in Phase 3, and represents the company's "next big hot button." NeuVax isn't just for breast cancer, though. GALE is also in Phase 2 trials with NeuVax plus Herceptin as a treatment for breast cancer, is in Phase 2 trials using the drug as a treatment for a different type of breast cancer, and the drug is even being tried as a therapy for prostate cancer; that trial is a Phase 1 test right now.
It can be a little unsettling for investors to know a company's nearly-entire pipeline is the same basic compound; if it doesn't work for one cancer, odds are good it won't work for others. Galena Biopharma Inc. isn't off-base with NeuVax, however. It's the real deal, and though it may not be approved for every indication it's being tested for, we've seen enough efficacy to offer hope for GALE investors. In the primary breast cancer trial, for instance, at 24 months, NeuVax patients were disease-free versus 86.8% of patients not taking the drug. At 60 months, 89.7% of NeuVax patients were disease-free versus 79.6% of patients in the control group.
Thing is, GALE isn't a "right here, right now" idea on the potential of NeuVax alone... there's a bit of an opportunistic angle here, fueled by a combination of timing and a technical catalysts (that may be tied together anyway).
As for the catalyst, while at Galena Biopharma may not have anything on the market and driving revenue yet, what's easy to miss about the company is that it has an approved drug it plans to begin marketing this year.
It's Abstral, for pain management in cancer patients. You've not heard much about it because it was approved a couple of years ago when a different company developed it and got the drug approved; Galena only decided recently to begin making it and selling it after buying the rights to it in the middle of this year.
Meanwhile, it was recently approved for use in Japan, so it may be over the proverbial hump in terms of getting enough revenue size and scale to make it with Galena's while. With much of this news staying off the radar, however, GALE is still something of an undiscovered opportunity. That condition is changing rapidly, however, if the shape of the GALE chart is any indication.
There's no denying GALE has been rallying nicely - even if modestly - since early 2012. But, the buying effort may be about to explode if shares can just get over the horizontal hurdle around $2.50 (which may be a possibility today). The convergence of the rising support line and a horizontal ceiling is putting a serious squeeze on the stock, and it looks like the bulls are drawing a tougher line in the sand than the bears are. We're also seeing more bullish volume than bearish volume here, so once the wedge pattern really starts to crumble, the flow should be an upward one. Indeed, some would argue that it already is. However, you see it, there's no denying that the news as well as the stock's momentum are starting to work together for the good of shareholders. This thing could get explosive real soon.
Grüsse aus der Schweiz
Zubi
Nach den ersten Pre-market Kursen habe ich mein Verkaufsorder, zum Glück, auf
2.95 abgeändert
Diesen schönen Gewinn nehme ich natürlich gerne mit
Bei einem Rückgang werde ich wieder eine Trader-Position eingehen. Dieses Spiel habe ich in diesem Jahre 2x erfolgreich abgeschlossen.
Meine Core-Position werde ich natürlich vor Kursen über 5.00 $ nicht anrühren.
Obwohl ich bei 3.00 $ exakt mit 100 % Gewinn dastehe
Grüsse aus der Schweiz
Zubi
PS am Sonntag geht es wieder für vier Wochen nach Denia (Costa Blanca)
2.95 abgeändert
Diesen schönen Gewinn nehme ich natürlich gerne mit
Bei einem Rückgang werde ich wieder eine Trader-Position eingehen. Dieses Spiel habe ich in diesem Jahre 2x erfolgreich abgeschlossen.
Meine Core-Position werde ich natürlich vor Kursen über 5.00 $ nicht anrühren.
Obwohl ich bei 3.00 $ exakt mit 100 % Gewinn dastehe
Grüsse aus der Schweiz
Zubi
PS am Sonntag geht es wieder für vier Wochen nach Denia (Costa Blanca)
Heute erstmals über 3+
Ich denke die werden sich weiter extrem raufhebeln in der nächsten Zeit. Ich warte noch mit dem Abverkauf....kaufe eher noch zu wenns nochmals günstig wird.
Ich denke die werden sich weiter extrem raufhebeln in der nächsten Zeit. Ich warte noch mit dem Abverkauf....kaufe eher noch zu wenns nochmals günstig wird.
Bin bei knapp unter USD 3 erstmal raus. Nach Einstieg bei den letzten zwei Kapitalerhöhungen ein guter Return von 50 bis 85% vor Steuern.
Am langen Ende bin ich nicht so extrem überzeugt, dass ich um jeden Preis halten möchte. Aber vielleicht komme ich in 2014 wieder richtig billig rein. Wenn nicht, egal.
Am langen Ende bin ich nicht so extrem überzeugt, dass ich um jeden Preis halten möchte. Aber vielleicht komme ich in 2014 wieder richtig billig rein. Wenn nicht, egal.
Kühlt schon wieder etwas ab... Denke GALE ist sehr interessant aber aktuell etwas überkauft.
Durchsuchen
